Risk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
In HR-positive/HER2-negative BC, proliferation rate as well as tumor grade correlated significantly with risk assessment by GEPs. Despite a high-risk result, chemotherapy is often omitted due to patient-specific factors such as age, comorbidities, or patients' preference. On the other hand, survival with genomic low-risk tumors is likely to be compromised to more advanced stage, questioning the clinical validity of GEPs in these cases.
Authors
- Elisabeth S. Gruber (ORCID: https://orcid.org/0000-0002-8646-1865)
- Zsuzsanna Bagó-Horváth (ORCID: https://orcid.org/0000-0002-8555-7806)
- Kerstin Wimmer (ORCID: https://orcid.org/0000-0001-5484-6229)
- Kristina Tendl-Schulz (ORCID: https://orcid.org/0000-0003-3288-8959)
- Rupert Bartsch (ORCID: https://orcid.org/0000-0002-4384-6917)
- Margaretha Rudas (ORCID: https://orcid.org/0000-0001-6267-0972)
- Maximilian Marhold (ORCID: https://orcid.org/0000-0001-8439-3312)
- Ruth Exner (ORCID: https://orcid.org/0000-0002-1168-1310)
- Alexa Binder
Institutions
- Comprehensive Cancer Center Vienna (AT)
Publication Details
- Journal
- Breast Care
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1159/000545785
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00